Fluo Labs, developer of drug-free seasonal allergy treatments, announces partnership with global life science company

0


[ad_1]

Fluo Labs Inc., a clinical pre-market medical device developer, announces its partnership with a leading global life sciences company, encouraging startups towards its goal of improving quality of life of people with allergies all over the world.

The medical technology company, established in 2020, is working on finalizing a revolutionary medical device that aims to dramatically improve the way people deal with allergic rhinitis, a condition commonly referred to as seasonal allergies or hay fever.

(Photo: Fluo Labs)

READ ALSO: Pollen allergy against COVID-19: how to tell the difference as the hot climate worsens the season

A drug-free allergy medicine with the support of a world leader

“It is difficult to tackle the growing problem of allergies. There has been little innovation in the field over the past 20 years,” said Lawrence Johnson, CEO of Fluo Labs. “We are thrilled to be pioneering a new category of nasal allergy care that will allow millions of people to get relief from their allergy symptoms without the need for medication. “

Johnson added that the next drug will be especially helpful for people who cannot take conventional allergy medications due to existing medical conditions or other contraindications.

With this new partnership, Fluo Labs management believes their plans will be accelerated, bringing their innovative solution to the rapidly growing respiratory care industry.

Fluo Labs’ response to allergic rhinitis is a technology based on photobiomodulation, a process that elicits a specific response in cells by exposure to light. The American Society of Laser Medicine and Surgery (ASLMS) describes it as a form of light therapy generally using non-ionizing light sources. This technology is harnessed by Fluo Labs to reduce inflammation in the nasal cavity and help reduce the release of histamine, making it a non-drug form of antihistamine.

The company already has successful proof of concept studies and is now undertaking the next step of its clinical and technical evaluation towards a De Novo grant from the Food and Drug Administration as well as CE certification.

In the same way, a 2020 study in the journal Medicine (Baltimore) evaluated the efficacy and safety of a light therapy process in the treatment of allergic rhinitis, which strengthens the credibility of the solution that Fluo Labs is actively seeking.

Fluo Labs is now close to a breakthrough, thanks to its team of experts in various fields such as light therapy, nasal steroids and antihistamines. Its future allergy care solution is the result of years of cutting edge research and relentless development in preclinical and clinical development, awarded two official patents and three more pending.

To further accelerate its growth, Fluo Labs is currently running a limited-time equity crowdfunding campaign on the StartEngine platform. Funds raised through the platform will be used to complete their product development and clinical evaluation. To invest, visit the Fluo Labs StartEngine webpage.

About Fluo Labs

Fluo Labs, Inc. describes itself as a “pre-market clinical stage medical device company with a mission to improve the quality of life of millions of people with seasonal allergies.” The company was founded by a team of passionate innovators with decades of industry experience developing advanced light-based medical devices, supported by extensive experience in the pharmaceutical and biotechnology industries that span virology. , drug therapies and light therapy.

Its technologies have already captured the attention of investors and communities, earning them the Best of CES 2021 award from Gear Diary, the Top Picks of CES 2021 award from Techlicious, as well as the finalist in P&G Ventures’ CES 2021 Innovation Challenge. .

RELATED ARTICLE: Study Suggests Climate Change Worsens Lives of Allergic People

Find more allergy news and information in Science Times.

[ad_2]

Leave A Reply

Your email address will not be published.